Anastasiya Nersesyan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anastasiya Nersesyan has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- M. E. Chernaya
Pavlov First Saint Petersburg State Medical University
7 shared publications - Anna R. Volkova
Pavlov First Saint Petersburg State Medical University
5 shared publications - Yurii Sh. Khalimov
Pavlov First Saint Petersburg State Medical University
5 shared publications - Y. A. Obiedkova
Pavlov First Saint Petersburg State Medical University
3 shared publications - Анна Владимировна Лискер
Pavlov First Saint Petersburg State Medical University
3 shared publications A Polushin
Pavlov University
1 shared publication
Latest Publications
- 18 May 2026
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 29 (2) , 157-168
Non-commercial insulin delivery closed-loop systems: results of comparative research with traditional methods of insulin therapy
BACKGROUND: The problem of achieving target glycemic control in patients with diabetes mellitus type 1 (T1DM) remains relevant. Currently, new, more technologically advanced methods of insulin therapy (IT) are being actively developed — one of them is the IT method of a closed loop (do-it-yourself closed loop system, DIY-CLS). This type of therapy is not registered in Russia, however, patients install these systems themselves, in connection with which it seems important to discuss the principle of DIY-CLS operation, the possibilities and prospects of their use. OBJECTIVE : To evaluate the glycemic control indicators, the frequency of acute complications of diabetes in patients with type 1 diabetes on different types of therapy. MATERIALS AND METHODS : We observed 98 patients who were divided into 3 groups: patients using MII (n=40), patients with CSII (n=40) and patients with DIY-CLS (n=18). All groups were comparable in age, sex and the duration of T1DM history. RESULTS: The majority of patients were women (73.47%), the average age was 33.3±2.4 years, the duration of diabetes was 17.1±2.2 years. It was found that in patients from the DIY-CLS group, compared with the MII and CSII groups, according to continuous glucose monitoring, the time in range was significantly higher, the mean glucose, standard deviation, time above range 10.1–13.9 mmol/l and time above range >13.9 mmol/l were significantly lower. The number of hypoglycemic states and hyperglycemic events leading to the development of ketosis was comparable. CONCLUSION: Glycemic control values were significantly better in patients using DIY-CLS. Patients in the DIY-CLS group more often achieved target time above range and coefficient of variation levels.
- 18 May 2026
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 29 (2) , 157-168
Non-commercial insulin delivery closed-loop systems: results of comparative research with traditional methods of insulin therapy
BACKGROUND: The problem of achieving target glycemic control in patients with diabetes mellitus type 1 (T1DM) remains relevant. Currently, new, more technologically advanced methods of insulin therapy (IT) are being actively developed — one of them is the IT method of a closed loop (do-it-yourself closed loop system, DIY-CLS). This type of therapy is not registered in Russia, however, patients install these systems themselves, in connection with which it seems important to discuss the principle of DIY-CLS operation, the possibilities and prospects of their use. OBJECTIVE : To evaluate the glycemic control indicators, the frequency of acute complications of diabetes in patients with type 1 diabetes on different types of therapy. MATERIALS AND METHODS : We observed 98 patients who were divided into 3 groups: patients using MII (n=40), patients with CSII (n=40) and patients with DIY-CLS (n=18). All groups were comparable in age, sex and the duration of T1DM history. RESULTS: The majority of patients were women (73.47%), the average age was 33.3±2.4 years, the duration of diabetes was 17.1±2.2 years. It was found that in patients from the DIY-CLS group, compared with the MII and CSII groups, according to continuous glucose monitoring, the time in range was significantly higher, the mean glucose, standard deviation, time above range 10.1–13.9 mmol/l and time above range >13.9 mmol/l were significantly lower. The number of hypoglycemic states and hyperglycemic events leading to the development of ketosis was comparable. CONCLUSION: Glycemic control values were significantly better in patients using DIY-CLS. Patients in the DIY-CLS group more often achieved target time above range and coefficient of variation levels.
- 1 January 2025
- Published by Geotar-Media Publishing Group in Endocrinology: News, Opinions, Training
- Vol. 14 (4)
Sarcopenia in young patients: accelerated muscle aging in type 1 diabetes mellitus
- 1 January 2025
- Published by Geotar-Media Publishing Group in Endocrinology: News, Opinions, Training
- Vol. 14 (4)
Sarcopenia in young patients: accelerated muscle aging in type 1 diabetes mellitus
- 1 January 2025
- Published by NP Rusmedical Group in Therapist’s Bulletin
- Vol. 67 (2)
Diabetic cardiovascular neuropathy: causes, consequences and modern treatment strategies
Aim. To study the causes, consequences, and current treatment strategies for the cardiovascular form of diabetic autonomic neuropathy. Key points. Diabetic cardiovascular autonomic neuropathy is a violation of the autonomic innervation of the cardiovascular system and an independent predictor of death in both patients with type 1 and type 2 diabetes mellitus. Chronic hyperglycemia plays a key role in the development of the disease. In the early stages, the parasympathetic division of the autonomic nervous system is affected, which is accompanied by relative sympathicotonia. As the disease progresses, the sympathetic division becomes involved, which leads to myocardial denervation. The diagnosis of diabetic cardiovascular neuropathy is based on a comprehensive examination of the patient and includes the use of the COMPASS-31 (Composite Autonomous Symptom Score 31) questionnaire, assessment of resting heart rate and heart rate variability, and cardiovascular tests. Prevention and treatment of this complication are aimed at reducing the risk of development and progression by improving glycemic control, as well as treating hypertension, dyslipidemia, and lifestyle modifications, including a balanced diet and increased physical activity. Conclusion. Diabetic cardiovascular autonomic neuropathy precedes the development of cardiovascular diseases in type 1 and type 2 diabetes mellitus. The clinical picture of this complication is diverse and inconspicuous, which leads to underestimation of the condition and emphasizes the need for timely diagnosis. Keywords: type 1 diabetes mellitus, type 2 diabetes mellitus, diabetic cardiovascular neuropathy.
- 1 January 2025
- Published by NP Rusmedical Group in Therapist’s Bulletin
- Vol. 67 (2)
Diabetic cardiovascular neuropathy: causes, consequences and modern treatment strategies
Aim. To study the causes, consequences, and current treatment strategies for the cardiovascular form of diabetic autonomic neuropathy. Key points. Diabetic cardiovascular autonomic neuropathy is a violation of the autonomic innervation of the cardiovascular system and an independent predictor of death in both patients with type 1 and type 2 diabetes mellitus. Chronic hyperglycemia plays a key role in the development of the disease. In the early stages, the parasympathetic division of the autonomic nervous system is affected, which is accompanied by relative sympathicotonia. As the disease progresses, the sympathetic division becomes involved, which leads to myocardial denervation. The diagnosis of diabetic cardiovascular neuropathy is based on a comprehensive examination of the patient and includes the use of the COMPASS-31 (Composite Autonomous Symptom Score 31) questionnaire, assessment of resting heart rate and heart rate variability, and cardiovascular tests. Prevention and treatment of this complication are aimed at reducing the risk of development and progression by improving glycemic control, as well as treating hypertension, dyslipidemia, and lifestyle modifications, including a balanced diet and increased physical activity. Conclusion. Diabetic cardiovascular autonomic neuropathy precedes the development of cardiovascular diseases in type 1 and type 2 diabetes mellitus. The clinical picture of this complication is diverse and inconspicuous, which leads to underestimation of the condition and emphasizes the need for timely diagnosis. Keywords: type 1 diabetes mellitus, type 2 diabetes mellitus, diabetic cardiovascular neuropathy.
- Open Access
- 27 June 2024
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 27 (3) , 277-286
Autologous hematopoietic stem cell transplantation as a method of immune prevention of type 1 diabetes mellitus: possibilities and prospects
Type 1 diabetes mellitus (DM) is one of the most common autoimmune disease that is treated with lifelong insulin therapy. Non-target indicators of glycemic control, which are observed in 71% of patients, lead to the formation and progression of diabetes complications, early disability and mortality. In this regard, the search for new approaches to the treatment and prevention of type 1 DM seems to be relevant. Various methods of immunological prophylaxis for the development of type 1 DM have been studied, in particular, the use of monoclonal antibodies. Thus, in November 2022, teplizumab was approved to slow down the clinical progression of the stage of type 1 DM. The prospects for the use of new options for islet cell transplantation are being studied — in June 2023, an allogeneic donor β-cell transplant obtained from the pancreas of donors after death was approved. Another pathogenetically substantiated method for the prevention and treatment of autoimmune diseases is high-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation (HDIT-HSCT). HDIT-HSCT demonstrated its effectiveness and cost-effectiveness in various clinical trials. This review provides up-to-date information on modern methods of immunological prophylaxis of type 1 DM.
- 27 June 2024
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 27 (3) , 277-286
Open AccessAutologous hematopoietic stem cell transplantation as a method of immune prevention of type 1 diabetes mellitus: possibilities and prospects
Type 1 diabetes mellitus (DM) is one of the most common autoimmune disease that is treated with lifelong insulin therapy. Non-target indicators of glycemic control, which are observed in 71% of patients, lead to the formation and progression of diabetes complications, early disability and mortality. In this regard, the search for new approaches to the treatment and prevention of type 1 DM seems to be relevant. Various methods of immunological prophylaxis for the development of type 1 DM have been studied, in particular, the use of monoclonal antibodies. Thus, in November 2022, teplizumab was approved to slow down the clinical progression of the stage of type 1 DM. The prospects for the use of new options for islet cell transplantation are being studied — in June 2023, an allogeneic donor β-cell transplant obtained from the pancreas of donors after death was approved. Another pathogenetically substantiated method for the prevention and treatment of autoimmune diseases is high-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation (HDIT-HSCT). HDIT-HSCT demonstrated its effectiveness and cost-effectiveness in various clinical trials. This review provides up-to-date information on modern methods of immunological prophylaxis of type 1 DM.
- Open Access
- 1 January 2024
- Published by Geotar-Media Publishing Group in Endocrinology: News, Opinions, Training
- Vol. 13 (3)
Asymmetric dimethylarginine as a marker of endothelial dysfunction in patients with type 1 diabetes mellitus with different glycemic variability
Асимметричный диметиларгинин как маркер дисфункции эндотелия у больных сахарным диабетом 1 типа с различной вариабельностью гликемии
- 1 January 2024
- Published by Geotar-Media Publishing Group in Endocrinology: News, Opinions, Training
- Vol. 13 (3)
Open AccessAsymmetric dimethylarginine as a marker of endothelial dysfunction in patients with type 1 diabetes mellitus with different glycemic variability
Асимметричный диметиларгинин как маркер дисфункции эндотелия у больных сахарным диабетом 1 типа с различной вариабельностью гликемии
- Open Access
- 1 January 2024
- Published by Geotar-Media Publishing Group in Endocrinology: News, Opinions, Training
- Vol. 13 (2)
Experience in using open-source automated insulin delivery systems in patients with type 1 diabetes mellitus
Опыт применения автоматизированных систем введения инсулина с открытым кодом у пациентов с сахарным диабетом 1 типа
- 1 January 2024
- Published by Geotar-Media Publishing Group in Endocrinology: News, Opinions, Training
- Vol. 13 (2)
Open AccessExperience in using open-source automated insulin delivery systems in patients with type 1 diabetes mellitus
Опыт применения автоматизированных систем введения инсулина с открытым кодом у пациентов с сахарным диабетом 1 типа
- 1 January 2022
- Published by Geotar-Media Publishing Group in Endocrinology: News, Opinions, Training
- Vol. 11 (4)
Fear of hypoglycemia: a new therapeutic target
Страх гипогликемии - новая терапевтическая мишень
- 1 January 2022
- Published by Geotar-Media Publishing Group in Endocrinology: News, Opinions, Training
- Vol. 11 (4)
Fear of hypoglycemia: a new therapeutic target
Страх гипогликемии - новая терапевтическая мишень